Rigel Pharmaceuticals, Inc. (RIGL): Price and Financial Metrics

Rigel Pharmaceuticals, Inc. (RIGL): $1.40

0.03 (+2.19%)

POWR Rating

Component Grades








Add RIGL to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals




#48 of 167

in industry

RIGL Price/Volume Stats

Current price $1.40 52-week high $2.04
Prev. close $1.37 52-week low $0.64
Day low $1.33 Volume 1,597,219
Day high $1.43 Avg. volume 2,929,933
50-day MA $1.27 Dividend yield N/A
200-day MA $1.28 Market Cap 243.13M

RIGL Stock Price Chart Interactive Chart >


  • Value is the dimension where RIGL ranks best; there it ranks ahead of 86.29% of US stocks.
  • RIGL's strongest trending metric is Value; it's been moving up over the last 179 days.
  • RIGL's current lowest rank is in the Stability metric (where it is better than 0.99% of US stocks).

RIGL Stock Summary

  • RIGEL PHARMACEUTICALS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 2.92% of US listed stocks.
  • RIGL's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 2.62% of US stocks.
  • Revenue growth over the past 12 months for RIGEL PHARMACEUTICALS INC comes in at 52.53%, a number that bests 88.06% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to RIGEL PHARMACEUTICALS INC are PLTK, QMCO, INTZ, WEJO, and AVID.
  • RIGL's SEC filings can be seen here. And to visit RIGEL PHARMACEUTICALS INC's official web site, go to www.rigel.com.

RIGL Valuation Summary

  • RIGL's price/sales ratio is 1.9; this is 62.75% lower than that of the median Healthcare stock.
  • RIGL's price/earnings ratio has moved down 3.9 over the prior 243 months.

Below are key valuation metrics over time for RIGL.

Stock Date P/S P/B P/E EV/EBIT
RIGL 2023-05-23 1.9 -10.2 -5.5 -6.5
RIGL 2023-05-22 2.1 -11.0 -6.0 -7.0
RIGL 2023-05-19 2.1 -11.3 -6.1 -7.2
RIGL 2023-05-18 1.7 -9.3 -5.1 -6.0
RIGL 2023-05-17 2.4 -13.0 -7.1 -8.2
RIGL 2023-05-16 1.7 -9.2 -5.0 -6.0

RIGL Growth Metrics

    Its year over year cash and equivalents growth rate is now at 23.11%.
  • Its 2 year cash and equivalents growth rate is now at -45.43%.
  • Its year over year revenue growth rate is now at -36.54%.
RIGL's revenue has moved up $30,085,000 over the prior 33 months.

The table below shows RIGL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 89.373 -70.935 -82.615
2022-06-30 88.506 -67.931 -84.53
2022-03-31 84.953 0.196 -84.859
2021-12-31 149.236 5.878 -17.914
2021-09-30 147.277 9.392 -14.51
2021-06-30 144.123 0.207 -7.732

RIGL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RIGL has a Quality Grade of B, ranking ahead of 89.87% of graded US stocks.
  • RIGL's asset turnover comes in at 0.825 -- ranking 30th of 682 Pharmaceutical Products stocks.
  • GERN, NEOG, and VNDA are the stocks whose asset turnover ratios are most correlated with RIGL.

The table below shows RIGL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.825 0.994 -0.082
2021-06-30 0.886 0.994 -0.034
2021-03-31 0.912 0.992 -0.069
2020-12-31 0.844 0.992 -0.296
2020-09-30 0.765 0.993 -0.259
2020-06-30 0.739 0.991 -0.220

RIGL Price Target

For more insight on analysts targets of RIGL, see our RIGL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.33 Average Broker Recommendation 1.33 (Strong Buy)

Rigel Pharmaceuticals, Inc. (RIGL) Company Bio

Rigel Pharmaceuticals, Inc. engages in the discovery and development of small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders. The company was founded in 1996 and is based in South San Francisco, California.

RIGL Latest News Stream

Event/Time News Detail
Loading, please wait...

RIGL Latest Social Stream

Loading social stream, please wait...

View Full RIGL Social Stream

Latest RIGL News From Around the Web

Below are the latest news stories about RIGEL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RIGL as an investment opportunity.

7 Growth Stocks That Are Too Cheap to Ignore Right Now

Although riskier than usual, these cheap growth stocks to buy now may help liven up your portfolio during these strange times.

Josh Enomoto on InvestorPlace | May 10, 2023

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2023 Earnings Call Transcript

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2023 Earnings Call Transcript May 2, 2023 Operator: Greetings, and welcome to the Rigel Pharmaceuticals Financial Conference Call for the First Quarter of 2023. At this time, all participants are in a listen only mode. A brief question-and-answer session will follow the formal presentation. As a reminder, this conference is […]

Yahoo | May 4, 2023

Q1 2023 Rigel Pharmaceuticals Inc Earnings Call

Q1 2023 Rigel Pharmaceuticals Inc Earnings Call

Yahoo | May 3, 2023

Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Tops Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 11.11% and 7.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 2, 2023

Rigel Reports First Quarter 2023 Financial Results and Provides Business Update

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2023, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment and sales of REZLIDHIA® (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitr

Yahoo | May 2, 2023

Read More 'RIGL' Stories Here

RIGL Price Returns

1-mo 17.65%
3-mo -13.58%
6-mo 67.97%
1-year -22.65%
3-year -28.39%
5-year -56.92%
YTD -6.67%
2022 -43.40%
2021 -24.29%
2020 63.55%
2019 -6.96%
2018 -40.72%

Continue Researching RIGL

Here are a few links from around the web to help you further your research on Rigel Pharmaceuticals Inc's stock as an investment opportunity:

Rigel Pharmaceuticals Inc (RIGL) Stock Price | Nasdaq
Rigel Pharmaceuticals Inc (RIGL) Stock Quote, History and News - Yahoo Finance
Rigel Pharmaceuticals Inc (RIGL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!